G protein‐coupled receptor family C, group 5, member D (GPRC5D), a member of the G protein‐coupled receptor (GPCR) family, has recently emerged as a promising target for immunotherapy in hematologic malignancies, particularly multiple myeloma. This evidence concerns the gene GPRC5D and hematologic disorder.